Vaccines Conferences | Immunology Conferences | Immunization Events | Asia Pacific | USA | Europe | 2017 | Japan

Theme:

Vaccines Asia Pacific 2017

Renowned Speakers

Chit Laa Poh
Sunway University
Malaysia

Andreas Suhrbier
QIMR Berghofer Medical Research Institute
Australia

Mohammed Alsharifi
The University of Adelaide
Australia

Tony Velkov
Monash University
Australia

GÃ¼lay BÃ¼yÃ¼kkÃ¶roÄŸlu
Anadolu University
Turkey

Tarl Prow
The University of Queensland
Australia

Kenneth Beagley
Faculty of Health, School - Biomedical Sciences
Australia

Istvan Toth
University of Queensland
Australia

Jean D. Boyer
Inovio Pharmaceuticals Inc.
USA

Andrew Lees
Fina Biosolutions LLC
USA

Adan Rios
PhotoImmune Biotechnology Inc.
USA

Timothy R Fouts
Profectus Biosciences Inc.
USA

Peter Burkhard
University of Connecticut
USA

Prakash Bhuyan
Inovio Pharmaceuticals
USA

Sean N Tucker
Vaxart Inc.
USA

Qingsheng Li
University of Nebraska-Lincoln
USA

Vaccines Asia Pacific 2017

ConferenceSeries Ltd invites participants from all over the world to attend 21^stAsia Pacific Global Summit on Vaccines & Vaccination during October 20-21, 2017 in Osaka Japan which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

Following the great success of the 12^th Asia Pacific Global Summit & Expo on Vaccines & Vaccination, November 24-25, 2016 in Melbourne, Australia, ConferenceSeries Ltd is organizing the 21^st Asia Pacific Global Summit on Vaccines & Vaccination which is going to be held during October 20-21, 2017 in Osaka Japan. This will be the latest in the Conference series LLC annual vaccine meeting series with 200+ Attendees, to provide a forum where key vaccine stakeholders including academic researchers, public health clinicians, veterinarians, vaccine policy makers, and manufacturers can exchange ideas and collaborate. There will be opportunities for those chosen to present at the meeting to publish a manuscript based on their presentation in the Journal of Vaccines & Vaccination or its sister publication, Immunome Research. ConferenceSeries Ltd organizes a conference series of 1000+ Global Events inclusive of 300+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

Why attend???

With members from around the world focused on learning about Vaccinology/Immunology and its advances; this is your best opportunity to reach the largest assemblage of participants from the Immunology/Vaccinology community. Conduct presentations, distribute information, meet with current and potential scientists, discuss the new vaccines developments, and receive name recognition at this event. World-renowned speakers, the most recent techniques, developments, and the newest updates in Immunology/Vaccinology are hallmarks of this conference.

Target Audience:

Vaccinology/Immunology Students, Scientists
Vaccinology/Immunology Researchers
Vaccinology/Immunology Faculty
Medical Colleges
Vaccinology/Immunology Associations and Societies
Business Entrepreneurs
Training Institutes
Software Developing Companies
Manufacturing Medical Devices Companies
Data Management Companies
Machinery Manufacturing Companies

- See more at: http://vaccines.global-summit.com/asia-pacific/index.php

Following the great success of the 12^th Asia Pacific Global Summit and Expo on Vaccines & Vaccination, November 24-25, 2016 in Melbourne, Australia, ConferenceSeries Ltd is organizing the 21^stAsia Pacific Global Summit on Vaccines & Vaccination which is going to be held in Osaka Japan during October 20-21, 2017.

This will be the latest in the ConferenceSeries Ltd annual vaccine meetings series with 200+ Attendees, to provide a forum where key vaccine stakeholders including academic researchers, public health clinicians, veterinarians, vaccine policy makers, Vaccine Research Development and manufacturers, Vaccine Business, Immunological Research and Vaccine Value Chain community, People focused on Immunoinformatics and Vaccines and Vaccine Informatics with the following profession areas: Innovators, Disruptors, and Influencers can exchange ideas and collaborate. There will be opportunities for those chosen to present at the meeting to publish a manuscript based on their presentation in the Journal of Vaccines & Vaccination or its sister publication, Immunome Research. ConferenceSeries Ltd organizes a conference series of 1000+ Global Events inclusive of 300+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

Track 1: Vaccines against Infectious diseases

New Vaccine techniques like in vitro gene-manipulation have opened up new approaches to vaccine development. This has rapidly grown into an exciting area of Vaccines against infectious diseases research in both academic and industrial laboratories. There are a number of scientific challenges which require multidisciplinary teams to solve problems in developing new immunogens. This has challenged our existing knowledge about protein structure and conformation, microbial pathogenicity and the immune system. Recombinant-DNA techniques are invaluable as tools of analysis and antigen production. The surface of micro-organisms can also be minutely explored with the use of synthetic peptides and monoclonal antibodies. Nevertheless, these new technologies do not allow us to circumvent the need for detailed understanding of pathogens and the disease process. A lot of researches are going on to improve/develope new vaccines and administration of vaccines

Vaccines Conferences, June 19-21, 2017, Paris, France; 15th Annual Summit on Vaccines and Immunization, February 20-21, 2017 German; 17th International Conference on Children Vaccines, August 21-22, 2017 UK; 18th Global Summit & Expo on Vaccines & Vaccination September 18-19, 2017 Houston, USA; 20th Asia Pacific Global Summit and Expo on Vaccines & Vaccination October 5-7, 2017, 2017 Kuala Lumpur, Malaysia; World Vaccine Congress Washington 2017 10 - 12 April, USA; International Conference on Vaccines, February 20-22, 2017 USA; 19th International Immunization Conference, June 25 - 26, 2017 France; 30th Annual Infectious Diseases in Children Symposium, November 18-19, 2017 USA; The 2017 Florida Immunization Summit, February 2-4, 2017 USA; HIV Vaccines, March 26—30, 2017 USA; IVW 2017 – Influenza Vaccines for the World, 19-21 April 2017 Switzerland; SVS 2017 – Immunization Event, 22-24 May 2017 The Netherlands.

Track 2: Cancer Vaccines

Mainly Cancer vaccines are two types preventive and therapeutic. Cancer preventive vaccines target infectious agents that cause or contribute to the development of cancer. They are similar to traditional vaccines, which help prevent infectious diseases. Polio Vaccines by protecting the body against polio. Both cancer preventive vaccines and traditional vaccines are based on antigens that are carried by infectious agents and that are relatively easy for the immune system to recognize as foreign.

Track 3: Hepatitis Vaccines

Viruses that primarily attack the liver are called hepatitis viruses. There are several types of hepatitis viruses including types A, B, C, D, E, and possibly G. Types A, B, and C are the most mundane. Viral Hepatitis B virus infection and C can cause chronic hepatitis. Vaccination for hepatitis makes the immune system to protect from hepatitis viruses.

Track 4: Bacterial Vaccines

Vaccine for antigenic substance prepared from the causative agent of a disease or a synthetic substitute, used to provide immunity against one or several diseases. Vaccination is one of the greatest breakthroughs in modern medicine. No other medical intervention has done more to save lives and improve quality of life. Bacterial vaccines contain killed or attenuated bacteria that activate the immune response. Antibodies are built against that particular bacteria, and prevents bacterial infection later. An example of bacterial vaccines is the tuberculosis vaccines

Track 5: DNA Vaccines

Genetic/ DNA immunization is a novel technique used to efficiently stimulate humoral and cellular immune response to protein antigens. The direct injection of genetic material into a living host causes a small amount of its cells to produce the introduced gene products. This inappropriate gene expression within the host has important Immunological Abnormalities, resulting in the specific immune activation of the host against the gene delivered antigen

Track 6: Combination Vaccines

The Number of Immunizations recommended is dramatically increasing day by day, especially for Childhood Vaccines United States the recommended immunization schedules for 2010 indicate that in the first 2 years children are expected to receive vaccines against 14 diseases. These combination Vaccine Adjuvants will deliver multiple vaccines in single visit/administration. Some of the combination vaccines are DTaP (DT) Vaccines, Tdap Vaccines etc.

Track 7: Edible vaccines

Edible vaccines and Recombinant Vector Vaccines mostly useful as these are easy-to-administer, cost-effective, Less Storage problems, and easily acceptable vaccine delivery system, especially for the poor or developing countries. It involves introduction of selected desired genes into plants and then inducing these altered plants to manufacture the encoded proteins. Introduced as a concept about a decade ago, it has become a reality today. A variety of delivery systems have been developed. Initially thought to be useful only for preventing infectious diseases, it has also found application in prevention of Autoimmunity related diseases, birth control, cancer therapy, etc.

Track 8: Viral vaccines

Viral vaccines contain either inactivated viruses or attenuated (alive but not capable of causing disease) viruses. Inactivated or killed viral vaccines contain viruses, which have lost their ability to replicate and in order for it to bring about a response it contains more antigen than live vaccines. Attenuated vaccines or live vaccines contain the live form of the virus. These viruses are not pathogenic but are able to induce an immune response.

Track 9: Vaccines against Vector borne Diseases

Mosquitoes, blackflies, sandflies, ticks, and lice are effective vectors of disease, transmitting pathogens via their blood meals. These Neglected Tropical Diseases (NTDs), are mostly diseases of poverty, and responsible for major economic burdens through disability, death of principal earners and missed educational opportunities for children and young adults, helping to maintain the poverty trap. It is no coincidence that the countries most affected by these diseases are also amongst the poorest countries in the world. Malaria is the most serious and costly of the insect-borne diseases with over 200 million cases of people being sick, and currently causing about 660,00 deaths per year, mostly children under the age of 5. The tragedy is that all these deaths could be stopped with a determined and coordinated approach.

Track 10: Travel Vaccines

The measles-mumps-rubella (MMR) vaccine is very important for travelers. Each year, unvaccinated people get measles while in other countries and bring it to the United States. This has sometimes led to outbreaks. Since 2000, when measles was declared eliminated from the U.S., the annual number of people reported to have measles ranged from a low of 37 people in 2004 to a high of 668 people in 2014. The majority of measles cases brought into the U.S. come from U.S. residents. When we can identify vaccine status, almost all are unvaccinated. However, it may not just be MMR vaccine that you need. You may be exposed to different diseases based on the countries you are visiting. For example, you may need the yellow fever vaccine if traveling to certain countries in Africa or Central or South America. If traveling to Asia, Latin America, or Africa, you may need typhoid vaccine.

Track 11: Mosquito-borne Diseases-Vaccines

Mosquito borne infectious diseases are among important group of diseases worldwide. Vaccination is available for some tropical mosquito-borne diseases, especially for Japanese encephalitis virus infection and yellow fever. There are also several attempts to develop new vaccines for the other mosquito-borne diseases such as malaria, dengue infection and West Nile virus infection.

Track 12: Protein Based Vaccines

Protein based subunit vaccines present an antigen to the immune system without viral particles, using a specific, isolated protein of the pathogen. A weakness of this technique is that isolated proteins, if denatured, may bind to different antibodies than the protein of the pathogen. Commonly used protein-based subunit vaccines.

Track 13: Toxoid Vaccines

Toxoid vaccines are made from a toxin (poison) that has been made harmless but that elicits an immune response against the toxin. are based on the toxin produced by certain bacteria (e.g. tetanus or diphtheria). The toxin invades the bloodstream and is largely responsible for the symptoms of the disease. The protein-based toxin is rendered harmless and used as the antigen in the vaccine to elicit immunity. Many companies’ immunoinformatics help full in this regard to increase the immune response what are the best measures, the toxoid is adsorbed to aluminium or calcium salts, which serve as adjuvants.

Track 14: Geriatric Immunization

Older adults are at increased risk for many vaccine-preventable diseases. Auto immunity is at low levels for older adults. Preventable illnesses cause substantial morbidity and mortality in older patients, who tend to have more medical co-morbidities and are at higher risk for complications. Acute respiratory infections, including pneumonia and influenza, are the 8th leading cause of death in the United States, accounting for 56,000 deaths annually. On average, influenza leads to more than 200,000 hospitalizations and 36,000 deaths each year (DHHS, Healthy People 2020).

Track 15: Immune mediated Diseases-Vaccines

Patients with immune-mediated inflammatory diseases (IMID) such as RA, IBD or psoriasis, are at increased risk of infection, partially because of the disease itself, but mostly because of treatment with immunomodulatory or immunosuppressive drugs. In spite of their elevated risk for vaccine-preventable disease, vaccination coverage in IMID patients is surprisingly low. This review summarizes current literature data on vaccine safety and efficacy in IMID patients treated with immunosuppressive drugs or immunomodulatory drugs and formulates best-practice recommendations on vaccination in this population. Especially in the current era of biological therapies, including TNF-blocking agents, special consideration should be given to vaccination strategies in IMID patients. Clinical evidence indicates that immunization of IMID patients does not increase clinical or laboratory parameters of disease activity. Live vaccines are contraindicated in immunocompromized individuals, but non-live vaccines can safely be given. Although the reduced quality of the immune response in patients under immunotherapy may have a negative impact on vaccination efficacy in this population, adequate humoral response to vaccination in IMID patients has been demonstrated for hepatitis B, influenza and pneumococcal vaccination. Vaccination status is best checked and updated before the start of immunomodulatory therapy: live vaccines are not contraindicated at that time and inactivated vaccines elicit an optimal immune response in immunocompetent individuals.

Track 16: Innovative Development of Vaccines

New technological advances have accelerated vaccine research and development (R&D) yielding numerous vaccines that have significantly reduced mortality and morbidity. In fact, each year, vaccines prevent up to 2.5 million child deaths. But a number of diseases still lack an effective means of prevention; some, like HIV and AIDS, are caused by complex viruses that despite significant progress to-date, have proven to be evasive of existing vaccine technologies. With the emergence and expansion of new diseases, the need and demand for innovative vaccines continues to grow. But vaccine development is a complex, arduous, and expensive process. It requires a mastery of multiple technologies, ample funds for clinical trials and manufacturing facilities, sophisticated scale-up processes, expertise in navigating demanding regulatory environments in various regions, and managing vigorous safety monitoring. The R&D-based vaccine industry’s knowledge and capacity make it well-positioned to develop and manufacture new vaccine candidates. While both public and private partners play vital roles in vaccine development, it is industry that generally drives and manages the overall process that results in the approval of a new Vaccine.

Track 17: Mucosal vaccines

Mucosal surfaces are enormous surface areas that are vulnerable to infection by pathogenic microorganisms. The adaptive immune system is designed to distinguish antigens, pathogens and vaccines that enter the body through mucosal surfaces from those that are introduced directly into tissues or the bloodstream by injection or injury. It is becoming increasingly clear that local mucosal immune responses are important for protection against disease: for example, autoimmunity of mucosal antibodies against Vibrio cholera bacteria and cholera toxin are associated with resistance to cholera, department cellular immunology is very helpful in mucosal vaccines formulation.

Track 18: Child hood and maternal vaccines

Auto immunity and Vaccines help make you immune to serious diseases without getting sick first. Without a vaccine, you must actually get a disease in order to become immune to the germ that causes it. Vaccines work best when they are given at certain ages. For example, children don't receive measles vaccine until they are at least one year old. If it is given earlier it might not work as well. The Centers for Disease Control and Prevention publishes a schedule for childhood vaccines, Adjuvants in Immunology is also plays an important role in vaccines formulation.

Track 19: Vaccines for unconventional diseases

When vaccines are mentioned most people think of immunization. Autoimmunity against childhood infectious diseases. However, in recent years the uses to which vaccines are being put has dramatically expanded beyond traditional infectious disease applications. Vaccines currently in preclinical and clinical development target prevention or treatment of a wide range of non-infectious diseases including cancer, allergy, asthma, diabetes, rheumatoid arthritis, lupus, hypertension, heart disease, obesity, Alzheimer’s disease, Parkison’s disease and even nicotine and cocaine addiction. For the most part such vaccines aim to induce neutralizing antibodies against foreign or self-antigens, thereby blocking their activity and ability to induce disease. This commentary reviews key clinical advances in the area of unconventional vaccines and identifies some of the key challenges that need to be overcome in order for unconventional vaccines and Immunomodulation research to move forward to medical and commercial success.

Track 20: Developing Conjugate Vaccines

A conjugate vaccine is created by covalently attaching a poor (polysaccharide) antigen to a carrier protein (preferably from the same microorganism), thereby conferring the immunological attributes/ Immunological Tolerance of the carrier to the attached antigen.

Track 21: Plant Derived Vaccines

Plants offer enormous potential as production platforms for vaccines and therapeutic proteins. Plant-derived vaccines, for example, present an alternative to conventional vaccines by facilitating safe and effective oral delivery through consumption of edible plant tissue. Many infectious diseases enter the body through mucosal surfaces such as the gut, and as a result, vaccines expressed in the form of edible plant tissues offer a select advantage. The plant tissues can protect the antigen as it passes through the digestive tract. Plants are capable of producing recombinant antigens that undergo similar post-translational modifications as their mammalian-derived counterparts and in contrast to bacterial expression systems. Moreover, high yields of biopharmaceuticals can be obtained, depending on the specific plant production platform. After these purification steps, the cost of producing plant-derived proteins represents only a fraction of the cost of proteins produced from analogous mammalian cell culture systems.

Track 22: Vaccines for Pregnant women and Neonates

There is a special CDC guidelines for the vaccines you need before, during, and after pregnancy. Some vaccines, such as the measles, mumps, rubella (MMR Vaccines) vaccine, should be given a month or more before pregnancy. You should get some vaccines, like Tdap (to protect against whooping cough), during pregnancy. Other vaccines, like the flu shot, can be given before or during pregnancy, depending on whether pregnant. It is safe for a woman to receive Human papilloma vaccines right after giving birth, even while she is breastfeeding. Be sure to discuss each vaccine with your health care professional before getting vaccinated.

Track 23: Animal Immunization

The major goals of veterinary vaccines and Preclinical Vaccine Studies are to improve the health and welfare of companion animals, increase production of livestock in a cost-effective manner, and prevent animal-to-human transmission from both domestic animals and wildlife. These diverse aims have led to different approaches to the development of veterinary vaccines from crude but effective whole-pathogen preparations to molecularly defined subunit vaccines, genetically engineered organisms or chimeras, vectored antigen formulations, and naked DNA injections. The final successful outcome of vaccine research and development is the generation of a product that will be available in the marketplace or that will be used in the field to achieve desired outcomes.

Track 24: Vaccines Adjuvants

The goal of vaccination is the generation of a strong immune response to the administered antigen able to provide long-term protection against infection. To achieve this objective with killed as opposed to live attenuated vaccines, often requires the addition of an adjuvant. Adjuvants are compounds that enhance the specific immune response against co-inoculated antigens.

Track 25: Vaccines Industry

The renaissance in the vaccine market continues with strong growth and new prospects to continue to grow this part of the market, which now stands at about $25 billion. Immunological Research Once a commodity market with low margins, the vaccines on the market now include blockbusters and mega blockbusters. New candidates for vaccinating against cancers and HIV Vaccines Research & Development are also projected to hit the magic milestone. The market is expected to return a compound annual growth rate of more than 8% through 2018, Evaluate Pharma projects, with some segments like adult vaccines showing even better.

Track 26: Vaccines Trials

Delivery of a vaccine in a programme such as Expanded Program on Immunization is the end result of years of discovery and development. Only a tiny percentage of candidate vaccines progress to licensing, making the costs of vaccine Research and Development extremely high. This fact also makes it essential to maintain a healthy product portfolio, with a range of vaccines at different stages in the pipeline.

Development of vaccines can be simplified into two broad stages:

Pre-clinical vaccines studies development is research carried out in lab assays and on animals. It includes: Immuno Thereapeutics Clinical development is when the vaccine is first tested in humans. It covers four stages over several years, from initial clinical trials in humans (phase I) right through to introduction and beyond (phase IV). Clinical development is built on rigorous ethical principles of informed consent from volunteers, with an emphasis on vaccine safety as well as efficacy.

Phase I clinical trials are small-scale trials to assess whether the vaccine is safe in humans and what immune response it evokes. For diseases of poverty this covers trials in European volunteers (phase Ia) and then in populations in Developing Countries (phase Ib).

Phase II clinical trials are larger and look mainly to assess the efficacy of the vaccine against artificial infection and clinical disease. Vaccine safety, side-effects and the immune response are also studied.

Vaccines that progress to phase III clinical trials are studied on a large scale of many hundreds of subjects across several sites to evaluate efficacy under natural disease conditions. If the vaccine retains safety and efficacy over a defined period, the manufacturer is able to apply to the regulatory authorities for a licence to market the product for human use.

The final phase IV happens after the vaccine has been licensed and introduced into use. Also called post-marketing surveillance, this stage aims to detect rare adverse effects as well as to assess long term efficacy.

Track 27: Vaccines Delivery Techniques

Currently excruciating research activity aimed at the development of incipient distribution systems for vaccines. The goal is to identify optimal methods for presenting target antigens to the Adaptive immunity in a manner that will elicit immune replications congruous for aegis against, or treatment of, a categorical disease. Several different approaches to this general goal have been developed, some are empirical and remain poorly understood, and others are more rational, being predicated, for example, on mimicking natural infections in vivo or on targeting particular features of the immune system. This article will review three categories of distribution systems: adjuvants and formulations; antigen vectors, including live attenuated micro-organisms and synthetic vectors; and novel contrivances for vaccine administration.

Track 28: Formulation

The renaissance in the vaccine market continues with strong growth and new prospects to continue to grow this part of the market, which now stands at about $25 billion. Once a commodity market with low margins, the vaccines on the market now include blockbusters and mega blockbusters. New candidates for vaccinating against cancers and HIV are also projected to hit the magic milestone. The market is expected to return a compound annual growth rate of more than 8% through 2018, Evaluate Pharma projects, with some segments like adult vaccines showing even better.

Track 29: Vaccines Business Development

Vaccines Business development: comprise a number of tasks and processes generally aiming at developing and implementing growth opportunities within and between organizations. It is a subset of the fields of business, commerce and organizational theory.

The 21^stAsia Pacific Global Summit on Vaccines & Vaccination to be held in Osaka Japan during October 20-21, 2017, hosted by Conference series LLC Conferences through the theme "Vaccines Research and Innovation", conference will explore the advances in vaccines and vaccination. This conference could be an exceptional event that brings along a novel and international mixture of giant and medium cognizance on vaccines and vaccination, leading universities engendering the conference an ideal platform to apportion expertise, foster collaborations across trade and world, and assess elevating technologies across the world. We Publish 400+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members and Organizes 300+ Conferences every year across USA, Europe & Asia with support from 1000 more scientific societies.

Vaccination is a key to eradicate the diseases. It is a subject for the professionals who look beyond the clinical prospects. Vaccines Asia Pacific 2017 amasses all the extroverts under one roof of current advances.

For more details please visit- http://vaccines.global-summit.com/asia-pacific/

Vaccinology is a major field in eradication of diseases. Traditional approaches to vaccine design were to emasculate or inactivate the human pathogen or a cognate animal homologue, Vaccinology is the science of vaccine development and how the immune system responds to vaccines, but additionally includes perpetual evaluation of immunization programs and vaccine safety and efficacy, as well as surveillance of the epidemiology of vaccine-preventable diseases. This chapter provides a brief overview of some of the main concepts of immunology and vaccinology as they relate to immunization.

Why Osaka?

In 2015 there were 30 vaccines and vaccine related conferences held in Japan. Among those 12 were from Osaka.

The bar graph illustrates the use of veterinary and human vaccines over a period of five years. Both veterinary and human vaccines market rate increased gradually from 2011 to 2015. Veterinary market rate rose from 4.47 B$ in 2011 to 5.6 B $ in 2015 whereas human vaccines market grew from 30.56 B $ to 58.6 B$ at 17.9% CAGR rate.

Conference Highlights:

· Technologies for the Design, Discovery, Formulation and Administration of Vaccines

· Developing Next-Gen Conjugate Vaccines

· New Trends in Carbohydrate-based Vaccines

· Vaccines for Pregnant Women

· Recent Advances in Animal Vaccination

· Adjuvants for Human Vaccines—Current Status, Problems and Future prospects

· Current Developments in Bacterial Conjugate Vaccines Potency

· Recent Trends in Attenuated Vaccines

· Advancements in Vaccine Development

· Vaccination and Quality of Life

Why to attend???

Vaccines Asia Pacific 2017 could be an event that brings along a novel and International mixture of giant and medium Vaccinology innovation and incipient trends in vaccines and vaccination, leading universities and vaccinology, vaccination research analysis establishments creating the conference an ideal platform to share expertise, foster collaborations across trade and world, and assess rising technologies across the world. World-renowned speakers, the most recent techniques, tactics, and the newest updates in Vaccinology research are hallmarks of this conference.

Major Vaccines Associations in & around Osaka.

Japanese Society for Immunology(JSI)
The Japanese Society for Vaccinology
The Japanese Society of Virology
The Japanese Association Of Medical Sciences
Japan Society of Immunology and Reproduction
Japan Pediatric Society

Major Vaccines Associations Globally

· The International Society for Interferon and Cytokine Research

· The International Society of Neuroimmunology

· The International Union of Immunological Societies

· The Society for Mucosal Immunology

· The Society for Leukocyte Biology

· Transplantation Society

· British Society for Immunology

· Cell Death Society

· European Federation of Immunological Societies

· European Society of Gene Therapy

· Federation of African Immunological Societies

· Federation of American Societies for Experimental Biology

· Federation of Clinical Immunology Societies

· Immune Deficiency Foundation

· Infectious Diseases Society of America

Target Audience:

Vaccines Asia Pacific-2017 Targets, CEO’s , Directors, Scientists, Professors, Students of all Biotech & Pharma companies, Universities and colleges globally

Vaccines sales in global leader companies 2012(1^st quarter):

· Pfizer 2.2 B $

· Sanofi 1.7 B $

· Merck & Co 1.8 B $

· GSK 2.5 B $

· Novartis 0.44 B $

· EBS 0.88 B $

The bar chart compares the vaccine sales in 2012 in the leading vaccines companies. GSK had the highest vaccines sales with 2.546 B $ followed by Pfizer, Merck & Co and Sanofi with 2.291 B $, 1.89 B $ and 1.755 B $ respectively. The lowest vaccines sale was in Novartis with 0.441 B$. Emergent Bio solutions had the next-lowest vaccine sales with 0.88 B $.

In and Nearby Universities

·University of Tokyo

·Kyoto University

·Osaka University

·International University of Japan

·United Nations University

·Waseda University

Top global Immunology Universities

Harvard University
University of California--San Francisco
Stanford University
Yale University
Johns Hopkins University
Washington University in St. Louis
Duke University
University of Pennsylvania
University of Texas Southwestern Medical Center--Dallas University of California San Francisco

Companies Associated with Vaccines

· CareDx

· Atara

· Bio therapeutics

· Benitec Limited

· InterMune

· Biotron Limited

· BioDiem

· Antisense Therapeutics Limited

· GlaxoSmithKline Australia Pty Ltd

· Bionomics

· Australian Pharmaceutical Industries (API)

· BioPharmica Limited

Market Analysis of Vaccines

Tripled in value from USD 5B in 2000 to almost USD 24 B in 2013, Global market projected to rise to USD 100 B by 2025. More than 120 new products in the development pipeline. 60 are of importance for developing countries. UNICEF had a market of 1,03 B$ in 2011, PAHO had 400 million dollars in 2011 and total UN market of 340 million dollars in 2002, 1,430 billion dollars in 2011.

Overall Statasticks

Conference Highlights

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date	October 20-21, 2017
Sponsors & Exhibitors	~~Click here for Sponsorship Opportunities~~
Speaker Opportunity Closed
Poster Opportunity Closed	Click Here to View

Useful Links

Special Issues

All accepted abstracts will be published in respective Our International Journals.

Abstracts will be provided with Digital Object Identifier by

21^stAsia Pacific Global Summit on Vaccines & Vaccination October 20-21, 2017 Melbourne, Australia

Recommended Global Vaccines Conferences

USA & Americas

Europe & Middle East

Asia Pacific

Meet Inspiring Speakers and Experts at our 1000+ Global Events inclusive of 300+ Conferences, 500+ Workshops and 200+ Symposiums Every year on Medical, Pharma, Engineering, Science, Technology and Business.

For more Conferences visit www.conferenceseries.com

Quick Links